Preventing Pandemics in an Interconnected World: the COVID-19 Story

Timothy Brewer, MD, MPH May 12, 2020

No relevant disclosures




Overview

- Factors contributing to emerging disease outbreaks
- Role of the World Health Organization in pandemic recognition and control
- COVID-19 origins and epidemiology
- Prevention, diagnosis, treatment and vaccine development



Outbreaks happen


- Zika
 - 87 countries/territories with outbreaks, 58 for first time in 2015 or 2016
- H1N1 Influenza (March 2009-Aug 2010)
 - 214 countries/territories, 18,449 lab confirmed deaths
- Ebola (March 2014-March 27, 2016; 10 countries)
 - 28,646 cases, 11,323 deaths (40% case fatality)
 - http://www.who.int/csr/disease/en/





Are Emerging Diseases Emerging?

- Emerging diseases increased between 1940 and 2004
- Bacterial or rickettsial pathogens accounted for just over half of all "events" (54.3%)
 - Includes drug-resistance
- 60.3% of emerging disease "events" were caused by zoonoses
 - 71.8% of zoonotic events involved wildlife pathogens





Year	Agent	Disease
1973	Rotavirus	Major cause of infantile diarrhea worldwid
1975	Parvovirus B19	Fifth disease; Aplastic crisis in chronic hemolytic anemia
1976	Cryptosporidium parvum	Acute enterocolitis
1977	Ebola virus	Ebola hemorrhagic fever
1977	Legionella pneumophila	Legionnaires' disease
1977	Hantaan virus	Hemorrhagic fever with renal syndrome (HFRS)
1977	Campylobacter sp.	Enteric pathogens distributed globally
1980	Human T-cell lymphotropic virus-I (HTLV I)	T-cell lymphoma leukemia
1981	Staphylococcus toxin	Toxic shock syndrome associated with tampon use
1982	Escherichia coli	Hemorrhagic colitis;
015	7:H7	hemolytic uremic syndrome
1982	HTLV II	Hairy cell leukemia
1982	Borrelia	Lyme disease
1	burgdorferi	
1983	Human immuno-	Acquired immunodeficiency
	deficiency virus (HIV)	syndrome (AIDS)
1983	Helicobacter	Gastric ulcers
	pylori	
1988	Human herpesvirus-6 (HHV-6)	Roseola subitum
1989	Ehrlichia chaffeensis	Human ehrlichiosis
1989	Hepatitis C	Parenterally transmitted non-A, non-B hepatitis
1991	Guanarito virus	Venezuelan hemorrhagic fever
1992	Vibrio cholerae	New strain associated with
	0139	epidemic cholera
1992	Bartonella	Cat-scratch disease; bacillary
	(= Rochalimaea)	angiomatosis
	henselae	
1993	Hantavirus isolates	Hantavirus pulmonary syndrome
1994	Sabia virus	Brazilian hemorrhagic fever


Some Major Diseases and Agents identified since 1973

Social, economic and environmental factors are believed to contribute to the emergence of new diseases, but the extent and relative importance different factors are unknown.




Source: CDC

Economic impact of selected outbreaks



Newcomb J. The economic impact of selected infectious disease outbreaks. Cambridge, M. Bio Economic Research Associates, 2011.

Where Emerging Diseases Emerge





Why outbreaks emerge

Genetic and biological factors

- Microbial adaptation and change
- Human susceptibility to infection

Physical environmental factors

- Climate and weather
- Economic development and land use

Ecological factors

- Changing ecosystems
- Human demographics and behavior


Social, political, and economic factors

- International travel and commerce
- Poverty and social inequity
- War and famine
- Lack of political will
- Intent to harm





Human environment interface



http://www.nytimes.com/learning/general/ont hisday/harp/0722_big.html

- French period,1881-1889
 - As many as 22,000
 workers die from Yellow
 Fever & malaria
- US Period 1904-1909
 - Malaria deaths drop from 11.59/1,000 (1906) to 1.23/1,000 (1909)
 - http://www.cdc.gov/malar ia/about/history/panama _canal.html

Human animal interface

- Middle East Respiratory Syndrome coronavirus (MERS-CoV)
 - 2494 cases, 858 deaths as of May 8th
 - MERS-CoV genetic sequences and antibodies found in camels and humans
 - People who work with camels at higher risk
 - Limited human to human transmission
 - http://www.who.int/emer gencies/mers-cov/en/





Humans, animals and the environment

- Malaysia/Singapore Nipah Virus Outbreak
 - 276 cases between1998-1999
 - 105 deaths (40%)
 - Natural reservoir flying foxes
 - Pteropus hypomelanus
 - Respiratory illness in pigs
 - Encephalitis in humans
 - Epstein. Curr Infect Dis Rep 2006; 8:59-65.








Trade: intended and unintended global distributions






Kraemer et al. eLife 2015;4:e08347

 A albopictus mosquitoes were introduced through used tires into the **United States in 1986** and spread broadly, and was the main vector identified in the dengue outbreak in Hawaii in 2001-02



Travel is faster, and more people are traveling

- 1.4 billion tourists traveled internationally in 2019
 - Increased every year since 2010
- Singapore to New York
 - 15,353 kms, 17.8 hours
 - https://upgradedpoints.
 com/longest-nonstopflights-in-the-world



https://www.eunwto.org/doi/pdf/10.18111/9789284421152



When Outbreaks do become International Concerns?

- Unknown disease
- Potential for spread beyond national borders
- Serious health impact or unexpectedly high rates of illness or death
- Potential for interference with international travel or trade
- Strength of national capacity to contain the outbreak
- Suspected accidental or deliberate release



International Health Regulations (IHR)

- Legally binding agreement adopted by 194 countries in 2005
 - Went into effect June 15, 2007
- Important changes
 - All public health threats
 - "illness or medical condition, irrespective of origin or source, that presents or could present significant harm to humans"
 - Obligation of member states
 - Develop minimal core public health capacity
 - Notify WHO about possible public health emergencies of "international concern"

West Nile Virus

- Single stranded RNA virus (Flavivirus)
 - Member of Japanese encephalitis serocomplex
 - Includes St. Louis encephalitis
 - Initially described in humans in 1937 in Uganda
 - Confined to Africa, the Middle East and Europe.
 - First North American case reported in August, 1999 in Queens, New York
 - Peterson et al. Ann Intern Med 2002;137:173.




A Tale of Two Birds









Lanciotti. Science 1999;286:2333





























Why do epidemics occur-summary

- Infectious diseases outbreaks are increasingly being recognized worldwide
 - Improved technology and reporting
 - Social and environmental changes drive new outbreaks
 - Urbanization, poverty, civil unrest, climate change
 - Travel and trade contribute to spread of infectious diseases




Coronaviruses



- Large single stranded RNA viruses
 - 4 genera α , β , γ , δ
 - $-\alpha$ and β coronaviruses
 - Respiratory tract infections in humans
 - Gastroenteritis in animals



SARS-CoV-2




- Zoonosis
 - Closely related to bat viruses (SL-CoVZC45 & SL-CoVZXC21)
 - Likely intermediate host animal
 - Binds to ACE-2 receptor in humans
 - Lu. Lancet
 2020;395:565-74.

Cui. Nature Rev Micro 2019;17:181-92.



Coronavirus life cycle







COVID-19 Epidemiology

- Severe pneumonia of unknown etiology recognized in Wuhan, China in December, 2019
 - Initial cases had exposure to live seafood market or Wuhan
 - Isolated from respiratory secretions, saliva, stool
 - 16% (173/1099) had severe disease; 1.4% died
 - Guan. New Engl J Med 2020



SARS-CoV-2 transmission

- Primarily respiratory droplets
 - 3 to 6 feet highest risk
 - Can survive on surfaces for hours to days
 - Up to 72 hours on plastic or stainless steel
 - Asymptomatic and pre-symptomatic transmission occurs
 - Aerosol transmission possible but not assumed to be major contributor
 - Lai. Inter J Antimicrob Ag 2020;55; van Doremalen. New Engl J Med 2020; Rothe. New Engl J Med 2020; WHO Joint Commission China Report 2020.

COVID-19 May 10th

- 3.9 million cases; 274,361 deaths (world)
 - Case fatality rate 7.0%
- 1.3 million cases; 78,771 deaths (US)
 - CFR 6.1%
- 66,680 cases; 2745 deaths (CA)
 - CFR 4.1%
- 31,677 cases; 1530 deaths (LA)
 - CFR 4.8%
 - WHO, CDC, CADPH, LACDPH



Clinical Characteristics

- 5 to 6 day incubation
 - Range 1 to 14 days
- Fever, cough, dyspnea most common
 - Sore throat, loss of smell or taste, diarrhea, myalgias, fatigue
 - Rhinorrhea uncommon
 - Vasculitis (Kawasaki syndrome) and blood clots reported
 - Zhou. Lancet 2020;395:1054; Lai. Intern J Antimicrob Ag 2020;55; WHO Joint Commission China Report 2020.



COVID-19 Clinical Course

- 80% of patients have mild to moderate disease
- 14% have severe disease requiring hospitalization
 - $-RR \ge 30$, O2 sat ≤ 93%, PaO2/FiO2 < 300
- 6% have critical disease requiring ICU care
 - Respiratory or multiorgan failure or shock
 - WHO Joint Commission China Report 2020.



Clinical course for hospitalized patients

- 13 day median onset to dyspnea
- 20 days median viral shedding
- 22 days median illness onset to hospital discharge
- 18.5 days median time to death
 - Zhou. Lancet 2020;395:1054.



Age as risk factor for serious/critical disease/death

- Laboratory confirmed hospitalization rates (per 100,000 population)
 - ≥ 65 years old 162.2
 - 50-64 years old 79.0
 - 18-49 years old 26.2
 - 5-17 years old 1.0
 - 0-4 years old 2.4
- 9/37,308 deaths (0.02%) ≤ 14 years old
- 7.9% deaths (2965) < 55 years old
 - https://www.cdc.gov/coronavirus/2019-ncov/coviddata/covidview/index.html#hospitalizations




Risk factors in hospitalized patients

- Comorbid disease (adults)
 - Hypertension (59%), obesity (50%), diabetes (42%), CV disease (35%)
 - Only 8.5% of hospitalized patients without comorbid condition
- Gender and race
 - African Americans 27.5% cases, 36.8% of hospitalizations, 21.2% of deaths (18% of population)
- 42% of pediatric cases did not have a comorbid condition
 - 38% had obesity
 - https://www.cdc.gov/coronavirus/2019-ncov/coviddata/covidview/index.html#hospitalizations



Viral diagnostics

- Pathogen based
 - PCR (NP swab, sputum, stool, saliva)
 - Antigen (NP swab, saliva)
- Immune based (serology)
 - Blood, plasma



 Bird BH. Ann Rev Animal Biosci 2018;6:121.



Some testing issues

- 1,343 persons with COVID-19 symptoms in New York
 - 113/624 with PCR confirmed COVID-19 were weakly antibody positive or negative on initial testing
 - Optimal time for testing at least 3-4 weeks after symptom onset
 - 249 (19%) tested positive for nasopharyngeal SARS-CoV-2 RNA 3 to 14 days after symptom resolution (longest 28 days)
 - Wajnberg. MedRxiv preprint 2020 https://doi.org/10.1101/2020.04.30.20085613



Radiology/laboratory findings

- Ground glass infiltrates on CT scan (86.2%) or chest x-ray
- Lymphopenia (83.2%, even with normal total WBC)
- Elevated inflammatory markers
 - CRP, D-dimer, LDH, ferritin, IL-6
- Age, D-dimer, organ failure associated with mortality
 - Guan. New Engl J Med 2020; Zhou. Lancet 2020;395:1054.



Antiviral Treatments

- Remdesivir only FDA approved treatment under EUA
 - Shortens duration of symptoms and hospitalization
- Non FDA approved treatments under study
 - Hydroxychloroquine, lopinavir/ritonavir, selinexor, favipravir, ribavirin
 - Convalescent serum



Immune modulating treatments – not FDA approved

- Cytokine storm in severe disease
- IL-6 blockers
 - Tocilizumab, sarilumab
- Janus associated kinase (JAK) inhibitors
 - Ruxolitinib, baricitinib
- CCR5 trafficking inhibitor
 - Leronlimab
- Steroids, interferon



Supportive and other care

- Oxygenation
- Pressure support
- Organ failure
 - Renal replacement
- Antibiotics for secondary infections
- Prophylactic anticoagulation



Prevention and control

- Case identification, isolation and contact tracing
- Physical distancing
- Quarantine
 - "Stay-at-home", "lockdown"
- Hand washing
- Disinfection of surfaces
- Masks and facial coverings
- Vaccines



Containing outbreaks in an interconnected world

- Strengthen global response capacity
 - Create emergency fund, response center
- Improve regional/international coordination
- Diversify expertise
 - Few diplomats, economists, anthropologists, etc.
- Engage civil society
- Improve monitoring of International Health regulations
 - Gostin. Lancet 2015;385:1902; Sands. New Engl J Med 2016;345:1281.



Thank you

Questions

